Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Novo Nordisk (NVO, Financial) shares fell 8% on Monday morning following disappointing Phase 3 trial results for its weight ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in ...

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...

Novo Nordisk's new drug, CagriSema, showed promising results in reducing weight among overweight or obese type 2 diabetes patients. During the phase III REDEFINE 2 trial, participants experienced a 15 ...

Novo Nordisk's trial results for CagriSema, a next-gen obesity and diabetes drug, showed a 15.7% weight reduction in overweight patients with type 2 diabetes. Despite promising outcomes, shares ...

Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

of CagriSema in overweight or obese patients without type 2 diabetes. Headquarters of pharmaceutical company Novo Nordisk in Copenhagen, Denmark, on Sept. 26, 2023. (Tom Little/File photo ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...